How many insider trades does FilingIQ track for APRE?

FilingIQ tracks 202 Form 4 insider transactions for APRE (Aprea Therapeutics, Inc.), covering filings from Oct 7, 2019 onwards. 8 of those were filed in the last 90 days.

Are APRE insiders net buyers or net sellers?

Across the full Form 4 history for APRE, 52 transactions (26%) were open-market purchases and 28 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does APRE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is APRE in?

Aprea Therapeutics, Inc. (APRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.19M.

APRE insider trading

NasdaqCM Healthcare

Aprea Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

202

Last 90 days

Buys / sells

26% / 14%

Market cap

$8.19M

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Company website: aprea.com

APRE insider activity at a glance

FilingIQ has scored 202 insider transactions for APRE since Oct 7, 2019. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 52 open-market purchases and 28 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on APRE insider trades is 57.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live APRE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading APRE

Gilad Oren

6 trades · score 70.0

Frequently asked

How many insider trades does FilingIQ track for APRE?: FilingIQ tracks 202 Form 4 insider transactions for APRE (Aprea Therapeutics, Inc.), covering filings from Oct 7, 2019 onwards. 8 of those were filed in the last 90 days.
Are APRE insiders net buyers or net sellers?: Across the full Form 4 history for APRE, 52 transactions (26%) were open-market purchases and 28 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does APRE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is APRE in?: Aprea Therapeutics, Inc. (APRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.19M.

Methodology & sources

Every APRE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.